{"id":240832,"date":"2026-05-07T07:00:00","date_gmt":"2026-05-07T11:00:00","guid":{"rendered":"https:\/\/news-you-need.com\/index.php\/2026\/05\/07\/eli-lilly-pledges-4-5bn-to-bolster-indiana-based-manufacturing\/"},"modified":"2026-05-07T07:15:10","modified_gmt":"2026-05-07T11:15:10","slug":"eli-lilly-pledges-4-5bn-to-bolster-indiana-based-manufacturing","status":"publish","type":"post","link":"https:\/\/news-you-need.com\/index.php\/2026\/05\/07\/eli-lilly-pledges-4-5bn-to-bolster-indiana-based-manufacturing\/","title":{"rendered":"Eli Lilly pledges $4.5bn to bolster Indiana-based manufacturing"},"content":{"rendered":"<p><a href=\"https:\/\/www.pharmaceutical-technology.com\/news\/eli-lilly-4-5bn-indiana-manufacturing-expansion-api-genetic-medicines\/\">Eli Lilly pledges $4.5bn to bolster Indiana-based manufacturing<\/a><\/p>\n<p><a href=\"https:\/\/www.pharmaceutical-technology.com\/news\/eli-lilly-4-5bn-indiana-manufacturing-expansion-api-genetic-medicines\/\">https:\/\/www.pharmaceutical-technology.com\/news\/eli-lilly-4-5bn-indiana-manufacturing-expansion-api-genetic-medicines\/<\/a><\/p>\n<p>Publish Date: <a href=\"publish_date]\">2026-05-07 07:00:00<\/a><\/p>\n<p>Source Domain: <a href=\"www.pharmaceutical-technology.com\">www.pharmaceutical-technology.com<\/a><\/p>\n<p>                                    Eli Lilly is expanding its presence within its home state of Indiana with a $4.5bn pledge to its Lebanon campus. Credit: rarrarorro \/ Shutterstock.com.<\/p>\n<p class=\"drop-cap\">Eli Lilly has shared plans to invest\u00a0a further\u00a0$4.5bn into its manufacturing presence in\u00a0Indiana, taking the pharma company\u2019s total investment into the state\u00a0to $21bn\u00a0since 2020.\u00a0\u00a0<\/p>\n<p>Through this commitment, Lilly will\u00a0expand operations across two of the three sites\u00a0on its\u00a0Lebanon campus \u2013 including the company\u2019s active pharmaceutical ingredient (API) production facility and its dedicated genetic medicines manufacturing centre, which opened on 6 May.\u00a0<\/p>\n<p><img decoding=\"async\" src=\"https:\/\/www.pharmaceutical-technology.com\/wp-content\/themes\/goodlife-wp-B2B\/assets\/img\/globaldata_marketing_solutions_logo.svg\" alt=\"\"\/><\/p>\n<h4> Discover B2B Marketing That Performs <\/h4>\n<p>\n\t\t\t\t\t\tCombine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.\n\t\t\t\t\t<\/p>\n<p>\n\t\t\t\t\t\t\tFind out more <span><\/span><\/p>\n<p>The API facility, which currently produces Lilly\u2019s best-selling tirzepatide franchise, will\u00a0now\u00a0be tailored to manufacture\u00a0the company\u2019s\u00a0newly approved\u00a0oral weight loss drug,\u00a0Foundayo\u00a0(orforglipron), which is currently\u00a0in the throes of its US launch. Prior to\u00a0Foundayo\u2019s\u00a0market debut, Lilly made several manufacturing investments\u00a0in the US,\u00a0China\u00a0and Europe\u00a0to keep up with potential demand for\u00a0the drug, while opting to create a\u00a0stockpile\u00a0to\u00a0further diminish the risk of shortages.\u00a0\u00a0<\/p>\n<p>Alongside\u00a0Foundayo\u00a0production,\u00a0Lilly\u2019s API facility will also manufacture the active ingredient in its \u201ctriple-G\u201d agonist,\u00a0retatrutide, which is currently in\u00a0late-stage trials\u00a0for obesity and type 2&#8230;<\/p>\n<p><a href=\"https:\/\/www.pharmaceutical-technology.com\/news\/eli-lilly-4-5bn-indiana-manufacturing-expansion-api-genetic-medicines\/\">Source<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Eli Lilly pledges $4.5bn to bolster Indiana-based manufacturing https:\/\/www.pharmaceutical-technology.com\/news\/eli-lilly-4-5bn-indiana-manufacturing-expansion-api-genetic-medicines\/ Publish Date: 2026-05-07 07:00:00 Source Domain:&#8230;<\/p>\n","protected":false},"author":1,"featured_media":240834,"comment_status":"closed","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"fifu_image_url":"https:\/\/www.pharmaceutical-technology.com\/wp-content\/uploads\/sites\/24\/2026\/05\/shutterstock_2147495375.jpg","fifu_image_alt":"","footnotes":""},"categories":[8],"tags":[],"class_list":["post-240832","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-technology"],"_links":{"self":[{"href":"https:\/\/news-you-need.com\/index.php\/wp-json\/wp\/v2\/posts\/240832"}],"collection":[{"href":"https:\/\/news-you-need.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/news-you-need.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/news-you-need.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/news-you-need.com\/index.php\/wp-json\/wp\/v2\/comments?post=240832"}],"version-history":[{"count":1,"href":"https:\/\/news-you-need.com\/index.php\/wp-json\/wp\/v2\/posts\/240832\/revisions"}],"predecessor-version":[{"id":240836,"href":"https:\/\/news-you-need.com\/index.php\/wp-json\/wp\/v2\/posts\/240832\/revisions\/240836"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/news-you-need.com\/index.php\/wp-json\/wp\/v2\/media\/240834"}],"wp:attachment":[{"href":"https:\/\/news-you-need.com\/index.php\/wp-json\/wp\/v2\/media?parent=240832"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/news-you-need.com\/index.php\/wp-json\/wp\/v2\/categories?post=240832"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/news-you-need.com\/index.php\/wp-json\/wp\/v2\/tags?post=240832"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}